ConductScience.org, home
primary myelofibrosis
API referenceFor AI assistants

Disease · MONDO_0009692

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

1 to 18 of 18

Download this page as JSON
ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Pacritinib vs Best Available Therapy: Spleen Volume Reduction42 of 2205 of 107327NCT01773187Trial comparisons
Pacritinib vs Best Available Therapy: deaths from any cause27 of 2203 of 106326NCT01773187Trial comparisons
Pacritinib vs Best Available Therapy: serious adverse events117 of 22033 of 106326NCT01773187Trial comparisons
Ruxolitinib vs Placebo: Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 2465 of 1551 of 153308NCT00952289Trial comparisons
Ruxolitinib vs Placebo: serious adverse events43 of 15553 of 151306NCT00952289Trial comparisons
Ruxolitinib vs Placebo: Number of Participants With a ≥ 50% Reduction in Total Symptom Score From Baseline to Week 2468 of 1488 of 152300NCT00952289Trial comparisons
Pacritinib vs Best Available Therapy: Total Symptom Score (TSS) Reduction19 of 1005 of 48148NCT01773187Trial comparisons
MMB 200 mg QD + Placebo vs DAN 300 mg BID + Placebo: Number of Baseline TD Participants With TI Status at Week 249 of 633 of 3497NCT04173494Trial comparisons
Treatment Arm vs Observation Arm: deaths from any cause0 of 50 of 38NCT01758588Trial comparisons
Treatment Arm vs Observation Arm: serious adverse events2 of 50 of 38NCT01758588Trial comparisons
Itacitinib 300 mg vs Total: deaths from any cause2 of 42 of 48NCT04629508Trial comparisons
Itacitinib 300 mg vs Total: serious adverse events3 of 43 of 48NCT04629508Trial comparisons
NS-018 vs Best Available Therapy (BAT): Change in Spleen Volume0 of 50 of 27NCT04854096Trial comparisons
NS-018 vs Best Available Therapy (BAT): Change in Spleen Volume1 of 50 of 27NCT04854096Trial comparisons
NS-018 vs Best Available Therapy (BAT): Change in Total Symptom Score (TSS)0 of 51 of 27NCT04854096Trial comparisons
NS-018 vs Best Available Therapy (BAT): deaths from any cause0 of 50 of 27NCT04854096Trial comparisons
NS-018 vs Best Available Therapy (BAT): Comparison of Treatment-emergent AEs Between NS-018 and BAT5 of 52 of 27NCT04854096Trial comparisons
NS-018 vs Best Available Therapy (BAT): serious adverse events1 of 50 of 27NCT04854096Trial comparisons

diseases-2026-09-18-0.1.0

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0009692/comparisons

API referenceFor AI assistants